| ||
| OXiGENE releases promising phase two data for lung cancer drug Proactive Investors USA & Canada "With several clinical trials completed in multiple indications, we now have a large body of data showing the excellent combinability potential of Zybrestat," said CEO Peter Langecker. "In addition, this study provides data in non-small cell lung ... See all stories on this topic » | ||
| Infinity Presents Data on Retaspimycin Hydrochloride, a Novel Hsp90 Inhibitor ... Benzinga Retaspimycin HCl is currently being evaluated in a Phase 2 trial in combination with docetaxel (also known as Taxotere ® ) in patients with non-small cell lung cancer (NSCLC). In a Phase 1b trial of retaspimycin HCl in combination with docetaxel in ... See all stories on this topic » | ||
| Cell>Point Presents Phase 2 Clinical Trial Results Comparing its 99mTc-EC-G ... Business Wire (press release) With the same EC-G "backbone"—and thus targeting mechanism—as 99m Tc-EC-G, 187 Re-EC-G is the company's first cold metallic cancer therapeutic and is a "companion" therapeutic to the diagnostic. The pre-clinical study looked at 12 Diffuse Large B ... See all stories on this topic » | ||
| Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker ... PR Newswire (press release) Capoxigem added to erlotinib therapy in a clinically relevant subset of biomarker-selected patients with advanced refractory non-small cell lung cancer significantly prolonged time to progression, progression-free survival and overall survival in a ... See all stories on this topic » | ||
| NewYork-Presbyterian/Weill Cornell Research Presented at American Society of ... Newswise (press release) The use of neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer (NSCLC) is controversial with trials consistently failing to demonstrate a significant benefit. The ability to identify chemoresponsive tumors should aid clinical trial design ... See all stories on this topic » | ||
| Infinity Presents Data on Retaspimycin Hydrochloride, a Novel Hsp90 Inhibitor ... istockAnalyst.com (press release) ... from a Phase 1b trial of retaspimycin hydrochloride (HCl) (also known as IPI-504), its novel heat shock protein 90 (Hsp90) inhibitor, in combination with docetaxel (also known as Taxotere ® ) in patients with non-small cell lung cancer (NSCLC). ... See all stories on this topic » | ||
| Blood Proteins May Identify Vulnerability of Pancreatic Cancers to Avastin HealthCanal.com It has been approved by the US Food and Drug Administration to fight colorectal, kidney, glioblastoma and non-small cell lung cancers, but against other cancers, Avastin has not had as much success. In a study reported last year, researchers at Duke ... See all stories on this topic » |
| ||
| OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug ... By Herina Ayot OXiGENE (NASDAQ:OXGN) shares rose in pre-market trading on Monday as it announced on the weekend that follow-up results from a phase two study of Zybrestat showed that patients with non-small cell lung cancer had better response and survival rates. The controlled, randomized trial, ... "With several clinical trials completed in multiple indications, we now have a large body of data showing the excellent combinability potential of Zybrestat," said CEO Peter Langecker. ... OneMedPlace - http://www.onemedplace.com/blog/ |
| ||
| Clinical outcome of cN0 non-small cell lung cancer patients staged ... Clinical outcome of cN0 non-small cell lung cancer patients staged by thin-slice CT, FDG-PET, and EBUS-TBNA. - ASCO - The American Society of Clinical ... www.asco.org/ASCOv2/Meetings/Abstracts?&...abst... | ||
| OXiGENE Reports Encouraging Data From Phase 2 Trial of ZYBRESTAT ... Non-small cell lung cancer patients with a poorer performance status also had a clinically meaningful increase in time to progression in patients. ... seekingalpha.com/.../1216995-oxigene-reports-encouraging-d... | ||
| New Study Released Today Showed Patients With Deadly Form of Lung ... About Non-Small Cell Lung Cancer (NSCLC) Globally, lung cancer is the most common form of cancer and the biggest killer, causing 1.3 million cancer deaths ... www.cnbc.com/id/43284658 | ||
| Feng Ming Spring Kong Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer ... www.labome.org/.../usa/.../feng-ming-spring-kong-831621.ht... |
Tip: Use a minus sign (-) in front of terms in your query that you want to exclude. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment